Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

23Andme Holding Co. (NQ: ME )

2.280 +0.030 (+1.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,519,835
Open 2.270
Bid (Size) 2.250 (20)
Ask (Size) 2.300 (1)
Prev. Close 2.250
Today's Range 2.230 - 2.300
52wk Range 2.020 - 6.310
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease
Company teams up with Novartis on Lipoprotein(a) education for 23andMe customers 
From 23andMe Holding Co.
Via Globe NewsWire
3 Key Ways That Artificial Intelligence Will Disrupt Biotech Stocks
Biotechs with an AI strategy are likely to be the first to flourish from the disruptions. 
Via The Motley Fool

Performance

YTD
+8.57%
+8.57%
1 Month
-2.15%
-2.15%
3 Month
+5.56%
+5.56%
6 Month
-20.28%
-20.28%
1 Year
-40.47%
-40.47%

More News

Read More
23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023
From 23andMe Holding Co.
Via Globe NewsWire
This Genetics Stock Could Have Massive Long-Term Potential
Via The Motley Fool
A Preview Of 23andMe Holding's Earnings
Via Benzinga
AI Revolution on the Horizon: 2 High-Potential Growth Stocks to Watch in 2023
Via The Motley Fool
New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare
From 23andMe Holding Co.
Via Globe NewsWire
2 Undervalued Growth Stocks With Long-Term Prospects That Are Ready to Rise
Via The Motley Fool
2 High-Growth Stocks That Could Double Your Money in 5 Years or Less
Via The Motley Fool
23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies
From 23andMe Holding Co.
Via Globe NewsWire
23andMe to Present at Upcoming Investor Conferences
From 23andMe Holding Co.
Via Globe NewsWire
Why Tivic Health Systems Are Trading Lower By 55%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
MGM Resorts, Madison Square Garden Entertainment, Cardiovascular Systems And Other Big Stocks Moving Higher On Thursday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
23andMe Reports FY2023 Third Quarter Financial Results
From 23andMe Holding Co.
Via Globe NewsWire
7 Former SPACs I Still Own (And What I Think Now)
Via The Motley Fool
23andMe to Report FY2023 Third Quarter Financial Results
From 23andMe Holding Co.
Via Globe NewsWire
3 Penny Stocks That Could Make You Filthy Rich
Via The Motley Fool
My 4 Worst-Performing Stocks and What I Think Now
Via The Motley Fool
Guardant Health, Novavax And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
Via Benzinga
25 Meme Stocks to Sell Before They Die
Via InvestorPlace
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
The Worst Investment Decision I Made in 2022
Via The Motley Fool
Why Iovance Biotherapeutics Shares Are Trading Higher By Around 19%? Here Are 40 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.